A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

Following the FDA ODD, European designation underscores ICT01’s potential as a ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Improving antimicrobial stewardship through novel anti-infectives is the need of the hour: Dr Surendran: Shardul Nautiyal, ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Intranasal delivery of a monoclonal IgG1 antibody targeting mugwort pollen protected mice from allergic rhinitis and asthma ...

Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...